Trial Profile
Phase II trial (Investigator-initiated clinical trial) of CH5424802 in patients with relapsed or refractory ALK-positive anaplastic large cell lymphoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Jan 2021
Price :
$35
*
At a glance
- Drugs Alectinib (Primary)
- Indications Anaplastic large cell lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms ALC-ALCL
- 01 Dec 2020 Primary endpoint (Overall response rate determined by Independent Review Facility), has been met according to results published in the Cancer Science
- 01 Dec 2020 Results published in the Cancer Science
- 20 Jul 2020 Status changed from active, no longer recruiting to completed.